Correct Answer: B. LMWH
This patient has multiple thromboembolism risk factors: preeclampsia (endothelial dysfunction, platelet activation), obesity (BMI 37), postoperative state (immobility, surgical trauma), and primigravida status (first pregnancy carries higher VTE risk). Low-Molecular-Weight Heparin (LMWH) is the gold standard for VTE prophylaxis in pregnancy and the immediate postpartum period because it does not cross the placenta, has predictable pharmacokinetics, and does not cause fetal complications. According to Indian guidelines (FOGSI, ICOG) and international consensus, LMWH is preferred over unfractionated heparin for extended prophylaxis in high-risk obstetric patients. The postoperative period (especially after cesarean) combined with preeclampsia and obesity places this patient in the high-risk category, warranting pharmacological thromboprophylaxis. LMWH can be safely continued in the postnatal period and during breastfeeding, making it the most appropriate choice for this clinical scenario.
Why the other options are wrong
A. Clopidogrel — Clopidogrel is an antiplatelet agent used for acute coronary syndromes and stent thrombosis, not for VTE prophylaxis in obstetrics. It has no role in preventing deep vein thrombosis or pulmonary embolism in the postpartum period. This option confuses antiplatelet therapy with anticoagulation—a common NBE trap in thromboprophylaxis questions. C. Warfarin — Warfarin is a vitamin K antagonist that crosses the placenta and is teratogenic (fetal warfarin syndrome), making it contraindicated in pregnancy and the immediate postpartum period. Although it may be used later for long-term anticoagulation, it is not appropriate for acute postoperative prophylaxis. This option tests knowledge of drug safety in obstetrics. D. Aspirin — Aspirin is an antiplatelet agent with weak anticoagulant properties, insufficient for VTE prophylaxis in high-risk obstetric patients. While aspirin may be used for preeclampsia prevention in future pregnancies, it does not provide adequate thromboembolism prophylaxis postoperatively. This option confuses preeclampsia management with VTE prevention.
High-Yield Facts
- LMWH is the first-line pharmacological thromboprophylaxis in pregnancy and postpartum period because it does not cross the placenta and is safe for breastfeeding.
- Preeclampsia + obesity + postoperative state = high-risk VTE category requiring extended prophylaxis (minimum 10–14 days postpartum, up to 6 weeks in severe cases).
- Warfarin is teratogenic (fetal warfarin syndrome) and is contraindicated in pregnancy; LMWH is preferred until postpartum when warfarin can be initiated if needed.
- Unfractionated heparin (UFH) is an alternative to LMWH but requires more frequent dosing and monitoring; LMWH is preferred for convenience and predictable pharmacokinetics.
- Mechanical prophylaxis (early mobilization, compression stockings) is adjunctive but insufficient as monotherapy in high-risk patients; pharmacological prophylaxis is mandatory.
Mnemonics
LMWH in OBG (SAFE) S = Safe in pregnancy (no placental crossing), A = Anticoagulant of choice, F = First-line for postpartum prophylaxis, E = Extended dosing for high-risk cases. Use this when deciding thromboprophylaxis in any pregnant or postpartum patient. VTE Risk in Obstetrics (PREOP) P = Preeclampsia, R = Recent surgery (cesarean), E = Elevated BMI, O = Older age/primigravida, P = Prolonged immobility. If ≥2 factors present, use pharmacological prophylaxis with LMWH.
NBE Trap
NBE pairs preeclampsia with aspirin (a known preventive agent) to lure students into confusing preeclampsia management with VTE prophylaxis. The question tests whether candidates understand that preeclampsia itself is a thrombotic risk factor requiring anticoagulation, not just antiplatelet therapy.
Clinical Pearl
In Indian tertiary centers, postpartum VTE is a leading cause of maternal mortality. A high-BMI primigravida with preeclampsia undergoing cesarean is at 4–5× baseline risk; LMWH prophylaxis for 10–14 days (or up to 6 weeks if severe preeclampsia) significantly reduces this risk and is now standard practice in most Indian obstetric units.
_Reference: DC Dutta's Textbook of Obstetrics (Ch. 23: Hypertensive Disorders in Pregnancy); FOGSI Guidelines on Thromboembolism in Obstetrics; Harrison Ch. 111 (Venous Thromboembolism)_